Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Idiotypic DNA vaccine
- Development stage
- Unknown
- Lead developer
- University of Texas MD Anderson Cancer Center
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This personalized DNA vaccine, developed by the M.D. Anderson Cancer Center, is an investigational immunotherapy designed for the treatment of chronic lymphocytic leukemia (CLL). The vaccine utilizes a DNA plasmid vector that incorporates the genetic sequence of the patient's own cancer cell immunoglobulin, specifically the idiotype. By delivering this genetic material via injection, the vaccine aims to induce the patient's immune system to mount both humoral and cellular responses against the unique idiotype expressed on the surface of their CLL cells. This approach is primarily evaluated in patients with previously untreated, early-stage (Binet Stage A) CLL to assess safety and the ability to shrink or slow the growth of the malignancy.
- Other names
- CLL DNA vaccineCLL vaccine using DNA plasmid vectorIdiotypic DNA vaccination
02
Targets
Id (Tumor-specific idiotype immunoglobulin)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on Idiotypic DNA vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Idiotypic DNA vaccine.